Pharma News, 2024

Indian drugmakers Aurobindo, Glenmark and Zydus have issued separate sweeping drug recalls over issues pertaining to impurities and labeling. The product pulls were reported in a recent edition of the...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug.

Gilead Sciences has entered a strategic partnership with Terray Therapeutics for the discovery and development of small-molecule therapies across several targets. The partnership leverages Terray’s ...

SK biopharmaceuticals said Tuesday that it has signed a collaborative research and development agreement with Korean biotech company ProEn Therapeutics to develop radiopharmaceutical therapies (RP...

Sun Pharma Advanced Research Company (SPARC) signed a binding Letter of Intent (LoI) with the University of California, San Francisco (UCSF), and Tiller Therapeutics Inc. for a...

AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments.

4D Molecular Therapeutics (FDMT) published landmark preclinical data in IOVS demonstrating the potential of its proprietary R100 vector and 4D-150 genetic medicine for treating neovascular ret...

The FDA has approved nemolizumab (Nemluvio; Galderma) for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids (TCS) and/or calcineurin inh...

The FDA granted an orphan drug designation to PLT012 (Pilatus Biosciences) for the treatment of patients with liver and intrahepatic bile duct cancer (HCC/ICCA).

COPENHAGEN - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company with a market capitalization of just under $7 million, has announced preclinical Proof-of-Concept (P...

China’s National Medical Products Administration (NMPA) has approved Santhera Pharmaceuticals’ AGAMREE (vamorolone), used to treat Duchenne muscular dystrophy (DMD) in pati...

If accepted, Vifor Pharma's £23m offer will "claw back" money for the NHS and close the CMA's first-ever disparagement case.